Dyslipidemia Management

My Settings
Relevant Content
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy
Polypharmacy is common in cardiovascular (CV) care because guideline-direc...
Researchers at Heart
Alterations in Cardiac and Systemic Metabolism in Heart Failure
Circulation: Heart Failure, Ahead of Print.
Altered cardiac and syste...
Vacuolar H+-ATPase Preserves Cardiolipin Homeostasis Through the Lysosomal-Mitochondrial Axis to Restrain Cardiac Aging
Circulation, Ahead of Print.
BACKGROUND:Cardiac aging involves progre...
Cost of Idling: Skeletal Muscle Myosin ATPase Dysfunction and the Energetic Basis of Exercise Intolerance in HFrEF
Circulation: Heart Failure, Ahead of Print.
Bile Acids, Mitochondria, and Myocardial Stiffness: A Shared Mechanism in Fontan Circulation and Metabolic Dysfunction-Associated Steatotic Liver Disease
Circulation: Heart Failure, Ahead of Print.
Is Placebo Still Ethical in Trials of Incretin Therapies?
Circulation, Volume 153, Issue 14, Page 1005-1008, April 7, 2026.
Cardiovascular–Kidney–Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study
Circulation, Ahead of Print.
BACKGROUND:Suboptimal cardiovascular–kid...
Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit
Circulation: Heart Failure, Ahead of Print.
Heart failure with preser...
Lipoprotein(a): An Atherosclerotic Cardiovascular Disease Risk Factor That Can No Longer Be Ignored